Clinical Trials Logo
  1. Home
  2. Advanced Biliary Tract Cancer
  3. NCT04217954

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Advanced Biliary Tract Cancer Clinical Trial

Official title:
Hepatic Arterial Infusion Chemotherapy With Oxaliplatin, 5-fluorouracil and Bevacizumab Plus Intravenous Toripalimab for Advanced Biliary Tract Cancer

Clinical Trial Summary

Hepatic arterial infusion chemotherapy (HAIC) deliver high concentration of chemotherapeutic agents directly to the liver tumor, was proved to be effective for intrahepatic and perihilar cholangiocarcinoma. Based on the potential synergistic effect of bevacizumab, chemotherapy and PD-1 inhibitor, this phase II clinical study want to test the efficacy and safety using intra-arterial infusion of oxaliplatin, 5-fluorouracil and bevacizumab combined with intravenous infusion of PD-1 inhibitor (Toripalimab) in the treatment of unresectable biliary malignant tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04217954
Study type Interventional
Source Peking University
Contact
Status Completed
Phase Phase 2
Start date July 28, 2020
Completion date June 1, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05009953 - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Phase 2
Recruiting NCT05820906 - Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer Phase 2
Completed NCT03358849 - Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer Phase 1
Recruiting NCT05410197 - Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN) Phase 2
Active, not recruiting NCT04727996 - Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Phase 2
Recruiting NCT05823987 - Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05) Phase 2
Not yet recruiting NCT04733521 - A Phase 1/2 Study of SC-43 in Combination With Cisplatin Phase 1/Phase 2
Recruiting NCT04027764 - Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer Phase 2
Recruiting NCT05781074 - Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08） Phase 2
Recruiting NCT04781192 - The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Phase 1/Phase 2
Recruiting NCT05653180 - IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer Phase 1/Phase 2
Recruiting NCT04005339 - NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer Phase 2
Recruiting NCT05170438 - Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment Phase 2
Active, not recruiting NCT04172402 - NGS as the First-line Treatment in Advanced Biliary Tract Cancer Phase 2
Withdrawn NCT02597465 - A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 Phase 3
Active, not recruiting NCT04969887 - Combination Immunotherapy in Rare Cancers Under InvesTigation Phase 2
Recruiting NCT04211168 - Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers Phase 2
Recruiting NCT05812430 - Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer Phase 2